Prostate And Other Male Cancers

Cancer Prevention Guidelines Updated

The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.

Calcium Associated With Lower Risk of Prostate Cancer

Dietary calcium intake is inversely associated with prostate-cancer risk, according to a study published online January 12 in the U.S. Centers for Disease Control and Prevention’s Preventing Chronic Disease.

Platinum Treatment for Testicular Cancer Ups Neurotoxicity

Long-term serum levels of residual platinum correlate with the severity of neurotoxicity five to 20 years after chemotherapy in testicular cancer (TC) survivors, even after adjusting for initial cisplatin dose, according to a study published online Dec. 19 in the Journal of Clinical Oncology.

PROLIA (denosumab) 60mg subcutaneous injection by Amgen

Prolia Gains Indications for Treatment of Bone Loss in Cancer Patients

Amgen announced that the FDA has approved Prolia (denosumab injection) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

Lupron Depot-6 Month 45mg Approved

Abbott announced that the FDA has approved a 45mg for six-month administration formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer.

ZYTIGA (abiraterone acetate) 250mg tablets by Centocor Ortho Biotech

Zytiga Approved for Metastatic Prostate Cancer

Centocor Ortho Biotech announced that the FDA has approved Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.